Navigation Links
GenVec Reports Fourth Quarter and 2010 Year-End Financial Results
Date:3/10/2011

4.4 million for services performed in 2010.
  • We achieved the first milestone in our research collaboration with Novartis which was triggered by the successful completion of certain preclinical development activities.  After this achievement, we are eligible to receive up to an additional $206.3 million in milestone payments if certain clinical, regulatory, and sales milestones are met, in addition to royalties on future sales.

  • VACCINES PROGRAMS

  • We entered into a Cooperative Research and Development Agreement with the U.S. Naval Medical Research Center (NMRC) to support their dengue fever vaccine research. Under a separate contract with the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., GenVec will receive funding for the development and preparation of vaccines related to this program.

  • Encouraging data were presented on GenVec's respiratory syncytial virus (RSV) vaccine program demonstrating preclinical proof-of-concept findings generated in multiple animal models at the National Institutes of Health (NIH) and GenVec. Specifically, the data show sustained production of neutralizing antibodies and the lack of immunological adverse events linked to prior unsuccessful RSV vaccine approaches.

  • SAIC-Frederick, Inc. executed its first option period (year two) under a previously announced four-year contract with GenVec for the development of influenza and HIV vaccines in support of the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases, part of NIH.

  • We published research describing GenVec's efforts to identify and utilize novel adenovirus serotypes as vectors in vaccine development.

  • Encouraging clinical and preclinical malaria vaccine data were presented indicating that our malaria vaccines given to malaria-naïve adults were found to be safe and well-tolerated. In addition, sterile protection, a complete absence of paras
    '/>"/>

  • SOURCE GenVec, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. GenVec Forms Collaboration With World-Leading Animal Health Company
    2. GenVec Reports Third Quarter 2010 Financial Results
    3. GenVec Receives Second-Year Funding From SAIC for HIV and Influenza Vaccine Development
    4. GenVec Receives National Cancer Institute Grant to Expand Cancer Program
    5. GenVec Announces Multiple Presentations at the American Society of Tropical Medicine and Hygiene Meeting
    6. Transgenomic Reports Fourth Quarter Financial Results
    7. Orexigen® Therapeutics Reports Fourth Quarter and Year Ended December 31, 2010 Financial Results
    8. Six-Month Prospective Multi-Center Study Reports Efficacy Rates for AMS Elevate Anterior and Apical Prolapse Repair System
    9. Sinovac Reports Positive Preliminary Phase I Clinical Trial Results for EV71 Vaccine in Adult Group
    10. Cardiogenesis Reports Fourth Quarter and Full Year 2010 Results
    11. Cellceutix Reports Confidential Disclosure Agreement Signed With Major Pharmaceutical Company
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/29/2014)... WASHINGTON , July 29, 2014 New ... in Medicare Part D by a projected $2.9 to ... by the actuarial firm Milliman released today by the ... Part D premiums could increase by as much as ... hepatitis C drugs, including Sovaldi and Olysio. ...
    (Date:7/29/2014)... Conn. , July 29, 2014 Numotion,s Board ... Mike Swinford will be the company,s new Chief ... highly successful 22-year career at GE where he worked primarily ... in annual revenue to over $5 billion. His most recent ... Services. "I am thrilled to join Numotion," ...
    (Date:7/29/2014)...  Roche (SIX: RO, ROG; OTCQX: RHHBY) launched its ... 2014 Clinical Lab Expo today by unveiling two booths ... is partnering with customers to redefine the value of ... day that they,re looking for a partner to help ... and offices," said Jack Phillips , president and ...
    Breaking Medicine Technology:New Milliman Study: Hepatitis C Drugs Could Increase Medicare Part D Spending by $2.9 to $5.8 Billion in 2015 2Numotion Names Mike Swinford CEO 2Roche focuses on partnering with customers to redefine the value of the laboratory at the AACC 2014 Clinical Lab Expo 2Roche focuses on partnering with customers to redefine the value of the laboratory at the AACC 2014 Clinical Lab Expo 3Roche focuses on partnering with customers to redefine the value of the laboratory at the AACC 2014 Clinical Lab Expo 4
    ... Oct. 26 Florida-based MEI Development Corporation, a ... acquired Georgia-based Oncology Business Advisory Group (OBAG) and ... as head of MEI Oncology Services.  MEI is ... industries, providing complete management of all aspects of ...
    ... Develop... -- INGELHEIM, Germany and ROCKVILLE, Md., Oct. 26 ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... { var s = ,; var first_result; // Results are keyed by longUrl, so we need to grab the ...
    Cached Medicine Technology:MEI Development Acquires Oncology Group; Names Founder as Head of Oncology Division 2Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics 2Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics 3Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics 4Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics 5Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics 6Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics 7Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics 8Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics 9Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics 10
    (Date:7/30/2014)... (PRWEB) July 30, 2014 BuyCBDOnline.co ... infused products, is pleased to announce that it is ... selection of top quality products available for immediate shipping. ... still in it's infancy stages," site founder Jason Liss ... already a wide variety of unique products that are ...
    (Date:7/30/2014)... 2014 The Independent Woman , ... holding 5 free financial workshops in the San Francisco ... goal of these workshops is our collective success, linking ... financial empowerment. , These workshops were designed by women, ... successful investor, entrepreneur, and bestselling author (Rich Woman and ...
    (Date:7/30/2014)... July 30, 2014 With the ... of personal health expenditure as well as the ... system, China diagnostic reagent industry has been developing ... 90%. In 2013, Chinese in vitro diagnostics market ... came from in vitro diagnostic reagents. , ...
    (Date:7/30/2014)... According to the Yeast Infection No More book ... that will help candida sufferers get rid of their ... uncovers to readers the truth about yeast infection and the ... people will discover natural and safe remedies to relieve symptoms ... and irritation of the vagina or vulva. , Vkool ...
    (Date:7/30/2014)... 30, 2014 My Clients Plus ... 80 different electronic therapy note templates. Healthcare providers ... other computing devices all while meeting the HIPPA ... electronic medial records (EMR) consist of psychological intake ... essential categories. SOAP and DAP note formats ...
    Breaking Medicine News(10 mins):Health News:Delicious, Unique CBD-Rich Hemp Oil Product Debuts from BuyCBDOnline.co 2Health News:Delicious, Unique CBD-Rich Hemp Oil Product Debuts from BuyCBDOnline.co 3Health News:The Independent Woman is Coming to the San Francisco Area in August - Women Helping Women Reach Their Financial Goals 2Health News:The Independent Woman is Coming to the San Francisco Area in August - Women Helping Women Reach Their Financial Goals 3Health News:China Diagnostic Reagent Industry (biochemical, molecular & immunodiagnostic) 2016 Forecasts in New Research Report at ChinaMarketResearchReports.com 2Health News:China Diagnostic Reagent Industry (biochemical, molecular & immunodiagnostic) 2016 Forecasts in New Research Report at ChinaMarketResearchReports.com 3Health News:China Diagnostic Reagent Industry (biochemical, molecular & immunodiagnostic) 2016 Forecasts in New Research Report at ChinaMarketResearchReports.com 4Health News:Yeast Infection No More Book Review Exposes Linda Allen's Guide for Treating Yeast Infection – Vkool.com 2Health News:Yeast Infection No More Book Review Exposes Linda Allen's Guide for Treating Yeast Infection – Vkool.com 3Health News:My Clients Plus Announces Over 80 Online Therapy Notes to Help Healthcare Providers Go Paperless 2
    ... reports of persistent,recent-onset symptoms linked to ovarian cancer ... full quickly and abdominal bloating -- when,combined with ... detection of,ovarian cancer by 20 percent, according to ... Center published online today in CANCER., Research ...
    ... inflammatory rheumatic disease, associated with stiffening of the vertrebral ... diagnosed in Germany, but milder forms of the disease ... Dr. Roland R. Wick, with Dr. Elke A. Nekolla, ... Dr. Wolfgang Gssner have conducted a long-term follow-up study ...
    ... Oral cannabis may even cause increased sensitivity in certain ... -- Oral cannabis (a form of medical marijuana) was ... actually increased sensitivity to some other kinds of discomfort, ... , Their study included 18 healthy women who ...
    ... might extend the effectiveness of clot-busting tPA, researchers say ... weapon against cancer might also boost stroke patients, survival, ... "wonder drug" against cancers such as chronic myelogenous leukemia ... boost the effectiveness and limit the side effects of ...
    ... More younger people than before are expected to ... acid in 2008, according to Millennium Research Group, ... Group (MRG),conducted a detailed survey focused on facial ... conference in San Antonio, Texas.,Over 60 US-based dermatologists ...
    ... $0.96 to $0.97 - - ... - Announces Additional ... Nash Corporation,(Nasdaq: KNSY ) today updated and expanded its previously announced ... to,include earnings per share estimates. In addition, the Company provided an,outlook for ...
    Cached Medicine News:Health News:Symptom Screening Plus a Simple Blood Test Equals a 20 Percent Jump in Early Detection of Ovarian Cancer 2Health News:Symptom Screening Plus a Simple Blood Test Equals a 20 Percent Jump in Early Detection of Ovarian Cancer 3Health News:Increased cancer risk following the use of radioactive Radium-224 in the therapy 2Health News:Medical Pot Ineffective as Acute Pain Treatment 2Health News:Cancer Drug Gleevec Could Fight Stroke 2Health News:Cancer Drug Gleevec Could Fight Stroke 3Health News:Younger Patients Seeking More Aesthetic Treatments 2Health News:Kensey Nash Provides 4th Quarter Fiscal 2008 and Fiscal Year 2009 Guidance 2Health News:Kensey Nash Provides 4th Quarter Fiscal 2008 and Fiscal Year 2009 Guidance 3Health News:Kensey Nash Provides 4th Quarter Fiscal 2008 and Fiscal Year 2009 Guidance 4Health News:Kensey Nash Provides 4th Quarter Fiscal 2008 and Fiscal Year 2009 Guidance 5Health News:Kensey Nash Provides 4th Quarter Fiscal 2008 and Fiscal Year 2009 Guidance 6Health News:Kensey Nash Provides 4th Quarter Fiscal 2008 and Fiscal Year 2009 Guidance 7Health News:Kensey Nash Provides 4th Quarter Fiscal 2008 and Fiscal Year 2009 Guidance 8Health News:Kensey Nash Provides 4th Quarter Fiscal 2008 and Fiscal Year 2009 Guidance 9
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    Medicine Products: